Compare Charles River Laboratories Intl. Inc (CRL) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Royal Caribbean Cruises Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $302.45 (market cap $14.23B), while Royal Caribbean Cruises Ltd trades at $280.82 (market cap $75.26B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 5.3× Charles River Laboratories Intl. Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| CRL | RCL | |
|---|---|---|
Market Cap | $14.23B | $75.26B |
Volume | 1,176,885 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $348.03 |
52-Week Low | $149.93 | $230.30 |
Typical Hold Time | 33 Days | 85 Days |
Enterprise Value | $17.06B | $97.91B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Royal Caribbean (RCL) trades at $280.65, down 0.61% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $17.93B, net income of $4.27B (23.54% margin), and consistent earnings beats in recent quarters. Recent news highlights include a $3B investment in Sandals Resorts and positive analyst sentiment with 52.83% buy ratings.
RCL presents a compelling growth story with strong profitability and expansion initiatives, though risks include high debt levels and fuel cost exposure. The consensus price target of $346.67 suggests 23.5% upside potential, supported by improving cash flow trends and strategic diversification into resort operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
